Pfizer's Lyrica fails to show post-traumatic nerve pain benefit; FDA approves Lilly lung cancer med Portrazza;

> Pfizer's ($PFE) Lyrica has failed to show benefit in patients suffering from a type of post-traumatic nerve pain in a late-stage study. Report

> The FDA has approved Eli Lilly's ($LLY) Portrazza to treat advanced squamous non-small cell lung cancer. Release

> Mylan has launched Clozapine orally disintegrating tablets--a generic of Jazz Pharmaceutical's ($JAZZ) FazaClo--in the U.S. Release

> The U.K.'s cost effectiveness gatekeepers have recommended two treatments for treating recurrent ovarian cancer, but they've rejected a further three. Report

And Finally... The Gaucher disease treatment market may reach $1.16 billion by 2024, GlobalData predicts. More

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.

Taking over IL-23 inhibitor brazikumab marks a new endeavor for AstraZeneca, as does buying prescription drugs Zenpep and Viokace for Nestlé.